Universal Beteiligungs und Servicegesellschaft mbH Buys 23,223 Shares of Bio-Techne Corp $TECH

Universal Beteiligungs und Servicegesellschaft mbH increased its position in Bio-Techne Corp (NASDAQ:TECH) by 54.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,186 shares of the biotechnology company’s stock after acquiring an additional 23,223 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Bio-Techne were worth $3,682,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in TECH. Oak Thistle LLC lifted its stake in shares of Bio-Techne by 1.9% during the 3rd quarter. Oak Thistle LLC now owns 9,314 shares of the biotechnology company’s stock valued at $518,000 after buying an additional 173 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Bio-Techne by 5.6% in the third quarter. Exchange Traded Concepts LLC now owns 3,630 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 192 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Bio-Techne by 11.8% in the third quarter. Farther Finance Advisors LLC now owns 1,883 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 198 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Bio-Techne by 5.6% in the second quarter. Parkside Financial Bank & Trust now owns 4,134 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 219 shares during the period. Finally, E Fund Management Co. Ltd. grew its position in shares of Bio-Techne by 4.5% during the second quarter. E Fund Management Co. Ltd. now owns 5,497 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 235 shares in the last quarter. Hedge funds and other institutional investors own 98.95% of the company’s stock.

Bio-Techne Trading Down 3.9%

Shares of NASDAQ TECH opened at $65.56 on Thursday. Bio-Techne Corp has a 1-year low of $46.01 and a 1-year high of $79.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.22 and a quick ratio of 2.81. The business’s 50 day moving average is $62.98 and its two-hundred day moving average is $58.75. The stock has a market capitalization of $10.21 billion, a P/E ratio of 133.80, a PEG ratio of 4.70 and a beta of 1.47.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. The business had revenue of $286.56 million during the quarter, compared to analyst estimates of $292.02 million. Bio-Techne had a return on equity of 13.59% and a net margin of 6.41%.The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same period last year, the company earned $0.42 EPS. As a group, research analysts expect that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 28th. Shareholders of record on Monday, November 17th were given a dividend of $0.08 per share. The ex-dividend date was Monday, November 17th. This represents a $0.32 dividend on an annualized basis and a yield of 0.5%. Bio-Techne’s payout ratio is 65.31%.

Analyst Ratings Changes

Several research firms have weighed in on TECH. Evercore ISI set a $62.00 price target on Bio-Techne and gave the stock an “in-line” rating in a research note on Monday, January 5th. Argus boosted their target price on shares of Bio-Techne from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft set a $72.00 target price on Bio-Techne and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, TD Cowen reissued a “buy” rating on shares of Bio-Techne in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.57.

Bio-Techne Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.